London South East | The UK's favourite investor portal.

LAD Ladbrokes They say Bookies are defensive stocks so just right at the moment. I hold LAD and was very convinced with last statement, it seems they are gearing the online side up substantially and should benefit from the Euros Football this summer. SP moved off bottom trendline yesterday within the uptrend channel. Im looking for a breakout of the channel and the former top initially at 140p or abouts, then after the summer a rise to 170p and above. P/E forecast to fall from 22 this year to 16 year 2017, rather cheap IMO. http://content.screencast.com/users/marketsniper/folders/Default/media/4dd5aed6-0aeb-430f-86b0-1d5c67b8e063/lad%202.jpg Ladbrokes Plc offers betting and gaming services.The company offers retail bookmaking in the United Kingdom, Ireland, Belgium and Spain.It offers betting markets on a daily basis via the Internet, mobile Internet and telephone. Valuation 2016e 2017e P/E ratio (Price / EPS) 21,9x 16,1x Capitalization / Revenue 1,04x 1,00x EV / Revenue 1,22x 1,16x EV / EBITDA 8,52x 7,69x Yield (DPS / Price) 2,52% 2,86% Price to book (Price / BVPS) 2,79x 2,63x

Standard Chartered : We have launched an exclusive investment opportunity for high net worth clients 03/03/2016 | 06:58am US/Eastern Standard Chartered announced the launch of its Pegasus Series programme, which offers private banking clients an exclusive opportunity to invest in leading private investment funds. With rising volatility in the investment landscape, high net worth investors who are able to take a long-term view are looking to private equity as an alternative asset class to diversify their portfolio for higher returns. Anna Marrs, CEO, Commercial & Private Banking, Standard Chartered Bank said: 'Over the last two to three years, we have seen growing interest among our clients - particularly family offices across Asia - in private equity as it becomes increasingly challenging to earn a decent yield from the public markets in today's low-interest rates environment.' This programme also offers investors the opportunity to gain exposure to industries and other asset classes that may be difficult to access on an individual basis. 'Not only are we able to provide this access at a substantially lower investment point, our clients can also leverage our partnerships with best-in-class managers to capitalise on opportunities that typically require a complex knowledge of the market,' noted Stanley Sia, Head, Private Equity & Real Estate, Group Wealth Management, Standard Chartered Bank. Anna Marrs added: 'This is part of a phased approach through which we offer our private banking clients a series of unique, customised and exclusive offerings to remain relevant to their needs. Particularly for the entrepreneurs across our footprint who are pre-disposed to external volatility through their businesses, we see this as a value-added solution to help them successfully diversify and grow their investment portfolio.' For further information please contact: Josephine Wong Manager, Commercial & Private Banking Communications Standard Chartered Bank +65 6596 4690 josephine.wong@sc.com

Chart of the week: This bank share could double By John Burford | Mon, 29th February 2016 - 11:07 Chart of the week: This bank share could double Today, I have two classic examples of the potential for big trading gains when you adopt a contrary stance once bearish sentiment has plumbed new depths. First, I will cover Standard Chartered (STAN) shares, which have been hammered in recent months for the well-known litany of woes of falling commodity prices, an economic slowdown in Asia and an urgency to sell off unprofitable businesses. But it is the stand-out chart pattern I wish to draw your attention to. Has Standard Chartered reached its low? The bad news about Standard Chartered probably reached a climax on Friday when Standard & Poor's (S&P) placed the bank on negative watch. Previously, it was judged stable with a rating of A+. That means that the next time it is reviewed by S&P, if its rating is lowered, it would place terrific strain on its ability to raise funds as cheaply as its competitors. But the really big hammer blow came last Tuesday when it reported a mammoth $1.5 billion (£1.1 billion) loss for the year compared with a $5.2 billion profit the previous year. That was some swing, and it hit the shares hard with a 10% decline that day. Since then, the market has recovered, so my question is this: was that plunge last week the final selling exhaustion of stale longs who finally threw in the towel? Are there any more of these holders who are waiting in the wings to unload? Or are the new buyers very astute and see the shares recovering as costs are being pared while commodity prices appear to be rebounding? As always, I look to the charts for answers. Here is the weekly chart showing the huge bear trend since 2013 from the 1,800p level down to last week's sub-400p low. http://content.screencast.com/users/marketsniper/folders/Default/media/0b894d9f-1242-423a-bf4e-674f2c201171/standard%20charted%202.jpg The two features that stand out for me are these: the lovely declining wedge going into the lows with the huge momentum divergence. Remember, a significant momentum divergence appearing after a lengthy trend (up or down) is a sign that the trend is very likely coming to an end. That is potentially a very bullish setup. Here is the latest action on the daily chart: http://content.screencast.com/users/marketsniper/folders/Default/media/83141fbd-04fe-4a21-adbe-06c7e227e023/standard%20charted%203.jpg This chart shows up the classic declining wedge pattern that contains a complete five-wave sequence complete with its own large momentum divergence. The market on Friday closed on the day's high touching the upper wedge line. Outlook If the market catches a bid and moves above the upper wedge line, that would help confirm the trend change to up. My first target becomes the 800p level, which is the wave four high (a common target). But, to activate that target, I ne

INVESTMENT OVERVIEW Clinigen unveils latest deal alongside strong set of interims Share 07:29 02 Mar 2016 The company's results reveal a company in rude health - and one still on the acquisition trial. Clinigen unveils latest deal alongside strong set of interims Clinigen seems to have found the formula for financial success. The ambitious specialty pharma group Clinigen (LON:CLIN) revealed the positive financial impact of a recent acquisitions and tie-ups as it unveiled its interim results. Alongside in a separate announcement it said it had bulked up its medicine cabinet with the acquisition of a product called Totect, which is used in cancer care. The terms of the deal with American firm Biocodex were not disclosed, although Clinigen said it is making an upfront payment along with further instalments over the next 12 months. Totect, which is also known as dexrazoxane, reverses the toxic effects of anthracycline, which is used in chemotherapy. It used to repair damage where the cancer drug accidentally leaks outside the vein and into the surrounding tissue. The acquisition, together with Clinigen’s purchase of Savene in 2014, gives the company “a complete global footprint” in this specialist area of medicine. David Moran, managing director of Clinigen’s speciality pharmaceuticals business, said the Totect was “a natural target for us as we continue to focus on acquiring niche, hospital-only therapies”. Separately, the group unveiled its first-half results, which showed a more than doubling of revenues to £157.1mln and a 74% rise in operating profits to £23.5mln. Clinigen’s cash balance grew by 96% compared with a year earlier to £22.1mln, while the interim dividend will be boosted by 18% to 1.3p a share. The results statement revealed the company is starting to feel the benefits from its £225mln purchase of Idis, a specialist in the ethical supply on unlicensed medicines, and Link Healthcare, which has become part of Clinigen’s managed access division. Its global footprint will expand further thanks to a global alliance with NASDAQ-listed Cumberland Pharmaceuticals. Today’s results release showed all the commercial and most of the operational integration is complete at Idis. The firm also told investors that a “revitalisation” of its newer products had driven the strong performance of its speciality pharma division. The company is positioned for a “good” second half, it added. "We have made significant progress towards meeting our strategic objectives as a result of the acquisitions of Idis in April and Link Healthcare in October last year, and our alliance with US Specialty Pharmaceuticals company, Cumberland Pharmaceuticals,” said chief executive Peter George. "We are firmly established as the global market leader in the management and supply of unlicens

SOM Somero....... http://www.investegate.co.uk/somero-enterprises--som-/rns/final-results/201603010700095484Q/ Current Trading and Outlook Healthy trading momentum in the US has carried forward into 2016 from the strong finish to 2015. The momentum is driven by demand for replacement equipment, fleet additions, technology upgrades and new products. The underlying non-residential construction market fundamentals in the US remain strong, evidenced by lengthy project backlogs for our customers that extend well into 2016. This gives us confidence in our growth prospects for 2016. In Europe, we are seeing similar carryover of momentum into 2016 which highlights a continued, steady recovery from the recessionary low point in 2010-2011. The momentum drivers in Europe are similar to the US. In the Middle East, coming off extraordinary growth in 2015, we expect to continue to see significant opportunities in 2016. In Latin America, we expect stable performance in Mexico and Chile and are optimistic for improvement in the other counties in the region outside of Brazil's economic challenges. The Asian markets remain positioned for improvement and will be primarily driven by increased penetration of our products. We expect to see greater need and willingness to use our products and services as acceptance of wide-placement and flatness, levelness standards grows. We will continue to support promotion of the benefits of using wide-placement processes to obtain high quality flat and level floors through our innovative Somero Concrete College initiative in China. In addition, we believe providing customers with Somero's new direct long-term financing options, which was enabled by development of Somero's proprietary machine shut-off capability, will have a positive impact on sales in the region. The Board believes the Company is well-positioned to capitalize on global market opportunities in the coming year and is confident Somero will deliver another year of solid growth.

Photo-Me's profits soar as Japanese ID business booms Share 08:01 26 Feb 2016 Upgrade of booths is France is also underway to meet new driving licence requirements Photo-Me's profits soar as Japanese ID business booms Photo-Me is going like a train in Japan Strong trading in Japan (LON:PHTM) and from its new automated laundries being rolled out in Europe sent profits at Photo-Me jumping by 90% its latest quarter. Japan is introducing new photo-ID cards and growth was driven by a strong start to the "My Number" programme. Overall, third quarter turnover was 11% higher with profits increased by 90%, compared to the same period last year. Profits for the year to April will now be in excess of £40mln and if the Japanese business continues its strong performance in the final quarter, the eventual outturn will exceed this, added Photo-Me. In addition, Photo-Me has started to upgrade its 22,000 photo booths to include next generation security measures such as biometrics and 3D. France will see the first of the new booths as its French subsidiary Photomaton has received approval from ANTS (France’s National Agency of Secure Documents) for a digitised e-photo and signature that is compliant with a new format of driving licence. The new licence incorporates holographic design and a machine readable zone (with the document sent from the sent from the photobooths via a secure server. Photo-Me has 7,800 photobooths in France and these will be upgraded and connected to a new secure to deployed nationally starting with Paris and the Ile-de-France. Approximately 2,000 machines should be upgraded by the end of June 2016, with the roll-out completed by the end of the year. Work is also underway in Germany, Switzerland and China. Serge Crasnianski, chief executive, said: "The overall performance of the business continues to be very good and we are obviously pleased that the ‘My Number’ programme in Japan has got off to such a strong start. “We have already begun to work with a number of Governments to deliver improved ID capture incorporating biometry and are very excited to be announcing this major new initiative in France". Share Philip Whiterow..... proactiveinvestors.co.uk

Latest Share Chat

Member Info for MickTKipper

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)

Latest Share Chat

Member Info for MickTKipper

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)

Please enter at least 2 characters

No results found

Search results

Recently viewed

Trending